A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
第一作者:
Nadia,Harbeck
第一单位:
Breast Center, Department of Obstetrics and Gynecology and CCC of LMU, University of Munich, Munich, Germany. nadia.harbeck@med.uni-muenchen.de.
作者:
医学主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗代谢药, 抗肿瘤(Antimetabolites, Antineoplastic);乳腺肿瘤(Breast Neoplasms);疾病恶化(Disease Progression);多柔比星(Doxorubicin);女(雌)性(Female);人类(Humans);中年人(Middle Aged);肿瘤转移(Neoplasm Metastasis);肿瘤分期(Neoplasm Staging);聚乙烯二醇类(Polyethylene Glycols);生活质量(Quality of Life);危险因素(Risk Factors);存活率分析(Survival Analysis);治疗结果(Treatment Outcome);青年人(Young Adult)
DOI
10.1007/s10549-016-4033-3
PMID
27798749
发布时间
2018-12-03
- 浏览65
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



